Patent Power: Roche Concedes Case Over Amgen's EPO
This article was originally published in The Pink Sheet Daily
Roche will not launch its anemia drug Mircera in the U.S. until Amgen's latest patent expires in 2015 unless it obtains a license.
You may also be interested in...
Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity
Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.
ESRD Market Snapshot: The Price Has To Be Right
The market for kidney disease drugs is under pressure from Medicare cost containment policies. However, there is still room for new drugs – if they can demonstrate a cost-savings benefit.
Roche Can Launch Mircera 10 Months Before Amgen's EPO Patent Expires
Amgen inked a license agreement with Roche in settling its patent infringement suit.